New Genentech Study to Investigate Familial Alzheimer’s Progression and Response to Crenezumab

New Genentech Study to Investigate Familial Alzheimer’s Progression and Response to Crenezumab
Genentech, a subsidiary of Roche, has launched a new substudy to learn more about the progression of early-onset familial Alzheimer’s disease, as part of its ongoing Alzheimer’s Prevention Initiative (API) trial evaluating crenezumab for preventing or delaying this genetic form of the disease. This substudy will examine the effects of presymptomatic treatment with crenezumab — an investigational anti-amyloid antibody under development by AC Immune and Genentech — on tau accumulation in the brains of patients at risk of familial Alzheimer’s. Data is expected to advance the understanding of how tau burden relates to disease progression and how it can be used to track crenezumab's efficacy in patients who respond to treatment. “Learning more about the early distribution and severity of Abeta [beta amyloid]- and tau-related pathology in AD [Alzheimer's disease] is imperative in developing successful Alzheimer’s treatments. This new substudy will provide further evidence on the progression of familial AD by monitoring for changes in Tau burden and help examine the potential role of crenezumab as a disease-modifying agent that may prevent the onset or slow progression in people at risk of developing familial AD,” Andrea Pfeifer, CEO of AC Immune, said in a press release. The study is part of API’s Phase 2 Autosomal Dominant Alzheimer’s Disease Colombia Trial (NCT01998841), which began in 2013 and is being led by Banner Alzheimer's Institute in Arizona, the University of Antioquia in Colombia, Genentech, and Roche. It enrolled about 200 members of an extended family in Colombia where several members carry the E280A mutation on the PSEN1 gene, one of the most common causes of early-onset familial autosomal dominant Alzheimer’s. Carrier
Subscribe or to access all post and page content.